Document is current
Any future updates will be listed below
-
Authors
Mezzanotte-Sharpe, Jessica
Hsu, Chih-Yuan
Choi, David
Sheffield, Hollie
Zelinskas, Sara
Proskuriakova, Ekaterina
Montalvo, Mateo
Lee, Danelle S.
Whisenant, Jennifer G.
Gaffney, Keaton
Thompson, Michael S.
Blenman, Kim
Tawagi, Karine
Symonds, Lynn
Santa-Maria, Cesar
Unni, Nisha
Quiroga, Dionisia
Shyr, Yu
Kennedy, Laura C.
-
Funding
Funding for this research was provided by:
VOLT T32 (2T32CA217834-07)
Carol and Jim O’Hare Fund
Robert A. Winn Career Development Award
- License Information
-
More Information
Article History
Received: 13 May 2025
Accepted: 4 June 2025
First Online: 4 July 2025
Declarations
:
: JMS, CYH, HS, SZ, DC, EP, MM, DSL, KG, JGW, and LS have no conflicts of interest to disclose. KT has served on advisory boards for Seagen and AstraZeneca. CMS has served on steering committees for Gilead and Greenwich Life Sciences and advisory boards for Merck, BMS, Pfizer, Lily, Daiichi/AstraZeneca, Seattle Genetics, CALIBR/SCRIPPs, and Immunomic Therapeutics. CSM has research support (to institution) from Merck, BMS, Pfizer, AstraZeneca, GSK, Celldex, Novartis, and Genentech. NU has COI to disclose for Pfizer and Gilead Sciences. DQ has received consulting fees from Cardinal Health, Inc. LCK has received consulting fees from AstraZeneca and Daiichi Sankyo as well as research funding from Roche-Genentech and Puma Biotechnology.
: This is an observational study. The VUMC IRB confirmed that no ethical approval was required.
: Due to the observational nature of this project as well as data de-identification, this work was granted a waiver of informed consent from the VUMC IRB.
